A Phase I/II Study of Pembrolizumab in Combination With Nab-Paclitaxel in Patients With Unresectable Stage III or Stage IV Non-Small Cell Lung Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 19 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting.
- 13 Apr 2016 New trial record